Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

The Alliance for Regenerative Medicine Releases Agenda for Third Annual Regen Med Investor Day
  • USA - English


News provided by

Linnden Communications

Mar 18, 2015, 09:00 ET

Share this article

Share toX

Share this article

Share toX

WASHINGTON, DC (PRWEB) March 18, 2015 -- The Alliance for Regenerative Medicine (ARM) today revealed its complete agenda for its upcoming third annual Regen Med Investor Day, taking place next Wednesday, March 25, 2015, in New York City. This event, held in partnership with Piper Jaffray and supporting bank Maxim, is a full-day conference expected to attract 350 attendees, including investors, members of the media and leading company executives.

This year’s event includes 32 company presentations and five expert-led sessions that will cover the future outlook for the industry, commercialization and market access strategies, capital markets, gene therapy delivery and anticipated clinical and commercial milestones for T-cell therapies.

“Investors are recognizing that our industry holds the key to the next-generation of transformational medical advances,” said Edward Lanphier, ARM Chairman and President and CEO of Sangamo BioSciences. “Advanced therapies, including regenerative medicines, gene therapy and modified cell therapies, have the capacity to create safe and effective treatments and potentially cures for patients around the world.”

2015 Panel Sessions and Speakers:

Fireside Chat: The Future Outlook for Advanced Therapies
Edward Tenthoff, Managing Director & Senior Research Analyst, Piper Jaffray (moderator)
Malcolm Brenner, M.D., Ph.D., Founding Director, Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children’s Hospital and The Methodist Hospital; Professor, Baylor College of Medicine
Olivier Danos, Ph.D., SVP, Gene Therapy, Biogen Idec

Market Access Strategies for Advanced Therapies
Jason Kolbert, Senior Managing Director, Maxim Group (moderator)
Brian Abraham, Senior Director, Market Access & Reimbursement, Nuo Therapeutics
John Doyle, Dr.P.H., SVP & Managing Director, Advisory Services, Quintiles
Michael Werner, Executive Director, Alliance for Regenerative Medicine; Partner, Holland & Knight

Fireside Chat: Capital Markets & Attracting Institutional Interest
C. Randal Mills, Ph.D. President & CEO, California Institute for Regenerative Medicine (introductory remarks)
James Douglas, Managing Director, Healthcare Investment Banking, Piper Jaffray (moderator)
Carl Gordon, Ph.D., Founding Partner & Co-Head of Global Private Equity, OrbiMed
Anthony Sun, M.D., Partner, Aisling Capital

Gene Therapy Delivery: What Can Be Accomplished with Existing Vector Technology & How Should We Expect It To Evolve?
Joshua Schimmer, M.D., Managing Director & Senior Research Analyst, Piper Jaffray (moderator)
David Kirn, M.D., CEO & Co-Founder, 4D Molecular Therapeutics
Richard Lawn, Ph.D., Consulting Professor, Cardiovascular Institute, Stanford University; Consulting Scientist, Cardiogen Sciences
Ken Mills, President & CEO, REGENXBIO
Steven Paul, M.D., CEO, Voyager Therapeutics

Adoptive T-Cell Therapies: Considering Key Upcoming Clinical & Commercial Milestones
Joshua Schimmer, M.D., Managing Director & Senior Research Analyst, Piper Jaffray (moderator)
Douglas Doerfler, President & CEO, MaxCyte
Thomas Farrell, President & CEO, Bellicum Therapeutics
Peter Ho, Ph.D., Director, Business Development, Lion Biotechnologies
Rick Morgan, Ph.D., VP, Immunotherapy, bluebird bio

2015 Presenting Companies:
AGTC, Argos Therapeutics, Asterias Biotherapeutics, Audentes Therapeutics, Avalanche Biotechnologies, bluebird bio, Bone Therapeutics, BrainStorm Cell Therapeutics, Capricor Therapeutics, Cardio3 BioSciences, Cellular Biomedicine Group, Cellular Dynamics International, Cesca Therapeutics, Fate Therapeutics, Fibrocell Science, Histogenics, Inovio Pharmaceuticals, Juventas Therapeutics, MaxCyte, MiMedx, NeoStem, Osiris Therapeutics, Oxford BioMedica, Pluristem Therapeutics, Regeneus, ReNeuron, Sangamo BioSciences, TiGenix, TxCell, Vericel, ViaCyte, Voyager Therapeutics

This event is held in partnership with Piper Jaffray and supporting bank Maxim Group. Industry sponsors include California Institute for Regenerative Medicine (CIRM), Cryoport, CTI Clinical Trial & Consulting Services, Kawasaki Heavy Industries, Lonza, NeoStem, PCG Advisory Group, Progenitor Cell Therapy (PCT) and TrakCel. Additional event supporters include Edison and The Life Sciences Report. The event will be held March 25, 2015, beginning at 7:30am at the Metropolitan Club at One East 60th Street in New York City.

For more information, please visit the event’s website at http://www.arminvestorday.com. Credentialed investors and life science strategic partners can indicate their interest in attending here: https://alliancerm.wufoo.com/forms/interested-in-attending-s1dlq2vs0yzpcya/. Members of the media interested in attending should contact Lyndsey Scull at lscull(at)alliancerm(dot)org.

About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 200 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit http://www.alliancerm.org.

Michelle Linn, Linnden Communications, +1 (774) 696-3803, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.